文献
J-GLOBAL ID:201802220810678668
整理番号:18A0856198
転移性結腸直腸癌(AXEPT)に対する第2選択療法としてのベバシズマブの有無による修正XELIRI(カペシタビン+イリノテカン)対FOLFIRI(Leucovorin,fluorouracil,およびイリノテカン) 多施設,オープンラベル,無作為化,非劣性,第3相試験【JST・京大機械翻訳】
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
著者 (21件):
Xu Rui-Hua
(Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Muro Kei
(Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan)
,
Morita Satoshi
(Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
,
Iwasa Satoru
(Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan)
,
Han Sae Won
(Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea)
,
Wang Wei
(Department of Gastrointestinal Oncology, The First People’s Hospital of Foshan, Foshan, China)
,
Kotaka Masahito
(Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan)
,
Nakamura Masato
(Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan)
,
Ahn Joong Bae
(Department of Internal Medicine, Severance Hospital, Yonsei University, Seoul, South Korea)
,
Deng Yan-Hong
(Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China)
,
Kato Takeshi
(Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan)
,
Cho Sang-Hee
(Department of Hematology-Oncology, Chonnam National University Hospital, Hwasun, South Korea)
,
Ba Yi
(Department of Digestive Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China)
,
Matsuoka Hiroshi
(Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan)
,
Lee Keun-Wook
(Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea)
,
Zhang Tao
(Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Yamada Yasuhide
(Department of Medical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan)
,
Yamada Yasuhide
(Department of Oncology, National Center for Global Health and Medicine, Tokyo, Japan)
,
Sakamoto Junichi
(Tokai Central Hospital, Kakamigahara, Japan)
,
Park Young Suk
(Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea)
,
Kim Tae Won
(Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea)
資料名:
Lancet Oncology
(Lancet Oncology)
巻:
19
号:
5
ページ:
660-671
発行年:
2018年
JST資料番号:
W1266A
ISSN:
1470-2045
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)